Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia

Immunotherapy has without question revolutionized the treatment of both hematologic and solid malignancies. Over the last several years novel strategies are being developed to incorporate these groundbreaking therapies into the care of patients with AML. Here we present an overview of the recent dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiatrowski, Kyle, Kim, Tae Hee, Przespolewski, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160191/
https://www.ncbi.nlm.nih.gov/pubmed/35664748
http://dx.doi.org/10.3389/fonc.2022.826768
_version_ 1784719221313241088
author Wiatrowski, Kyle
Kim, Tae Hee
Przespolewski, Amanda
author_facet Wiatrowski, Kyle
Kim, Tae Hee
Przespolewski, Amanda
author_sort Wiatrowski, Kyle
collection PubMed
description Immunotherapy has without question revolutionized the treatment of both hematologic and solid malignancies. Over the last several years novel strategies are being developed to incorporate these groundbreaking therapies into the care of patients with AML. Here we present an overview of the recent developments in immunotherapy for AML with a focus on biomarkers of response. Topics reviewed include antibody drug conjugates, BiTEs, DARTs, checkpoint inhibitors, and cellular therapy as well as the development of biomarkers predictive of response in each class.
format Online
Article
Text
id pubmed-9160191
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91601912022-06-03 Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia Wiatrowski, Kyle Kim, Tae Hee Przespolewski, Amanda Front Oncol Oncology Immunotherapy has without question revolutionized the treatment of both hematologic and solid malignancies. Over the last several years novel strategies are being developed to incorporate these groundbreaking therapies into the care of patients with AML. Here we present an overview of the recent developments in immunotherapy for AML with a focus on biomarkers of response. Topics reviewed include antibody drug conjugates, BiTEs, DARTs, checkpoint inhibitors, and cellular therapy as well as the development of biomarkers predictive of response in each class. Frontiers Media S.A. 2022-05-19 /pmc/articles/PMC9160191/ /pubmed/35664748 http://dx.doi.org/10.3389/fonc.2022.826768 Text en Copyright © 2022 Wiatrowski, Kim and Przespolewski https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wiatrowski, Kyle
Kim, Tae Hee
Przespolewski, Amanda
Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia
title Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia
title_full Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia
title_fullStr Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia
title_full_unstemmed Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia
title_short Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia
title_sort cellular and molecular biomarkers predictive of response to immunotherapy in acute myeloid leukemia
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160191/
https://www.ncbi.nlm.nih.gov/pubmed/35664748
http://dx.doi.org/10.3389/fonc.2022.826768
work_keys_str_mv AT wiatrowskikyle cellularandmolecularbiomarkerspredictiveofresponsetoimmunotherapyinacutemyeloidleukemia
AT kimtaehee cellularandmolecularbiomarkerspredictiveofresponsetoimmunotherapyinacutemyeloidleukemia
AT przespolewskiamanda cellularandmolecularbiomarkerspredictiveofresponsetoimmunotherapyinacutemyeloidleukemia

Ejemplares similares